The Russian State Research Center of Virology and Biotechnology Vector has started developing a new Coronavirus (COVID-19) vaccine in the form of nasal drops, an official said. Vector General Director Rinat Maksyutov said in an interview with Sputnik that the vaccine would help provide immunity right at the “entrance gate” of the infection, “Yes, we have started developing a vaccine in the form of drops, an intranasal vaccine. “The composition of the main active component of the vaccine will remain unchanged (same as that of the EpiVacCorona vaccine),” Maksyutov said. The vaccine will help develop immunity in the nasal mucous membranes, which can be described as the “entrance gate” of the infection, Maksyutov specified. NAN
Britain should give an alternative to Oxford/AstraZeneca's COVID-19 vaccine to under 30s where possible due to a "vanishingly" rare side effect of blood clots in the brain, Britain's vaccine advisory committee said on Wednesday. Officials said the benefits of the shot continued to outweigh its risks for the vast majority, after safety concerns spurred over a dozen countries in recent weeks to suspend use of the vaccine following reports linking it to a brain blood clotting disorder. Britain has kept using the shot throughout. Wei Shen Lim, chair of Britain's Joint Committee on Vaccination and Immunisation (JCVI), said that based on the available data and evidence, it was preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AstraZen...
Europe's drug regulator on Wednesday, April 7th found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot and said it had taken into consideration all available evidence. "One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin," the European Medicines Agency (EMA) said. The findings come as a major hurdle in the global fight against the pandemic and a shift in the stance of the regulator, which had last week backed the vaccine and said there was no increased risk of blood clots in general from the shot. It is also a blow to AstraZeneca, which was a frontrunner in the rac
A link between AstraZeneca’s COVID-19 vaccines and blood clots is plausible but unconfirmed, the World Health Organisation’s vaccine experts said Wednesday, stressing that reported occurrences were “very rare.” The statement came after the EU’s EMA drug regulator said Wednesday that blood clots should now be listed as a “very rare” side effect of the AstraZeneca coronavirus vaccine — adding that the vaccine’s benefits continue to outweigh the risks. The COVID-19 sub-committee of the WHO Global Advisory Committee on Vaccine Safety met on Wednesday to review the latest information from the EMA, British and other medicines regulators. “Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets i
The Federal Government has received 100,000 doses of Covishield vaccines from India. Covishield is Serum Institute of India’s version of AZD1222, the vaccine developed by AstraZeneca in collaboration with the University of Oxford. The Chairman of the Presidential Task Force on COVID-19 and Secretary to the Government of the Federation, Mr. Boss Mustapha, confirmed this on Tuesday at the national briefing by the PTF in Abuja. He said: “As you are aware, Nigeria received 3.94 million doses of the COVID-19 Oxford/AstraZeneca vaccine on March 2, 2021. “These vaccines represented the first tranche of about 16 million doses allocated to Nigeria through the COVAX facility, aimed at vaccinating an initial 20 percent of the population. “More vaccines are also expected from the Af